New drug tested in patients with liver disease: safety first

NCT ID NCT04534699

Completed Knowledge-focused Sponsor: KBP Biosciences Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This early-stage study looked at how the drug KBP-5074 behaves in people with moderate liver impairment compared to healthy volunteers. Twelve adults received a single dose, and researchers monitored safety and drug levels in the blood. The goal was to see if liver problems change how the drug is processed, which is important for future dosing recommendations.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: KBP-5074 (a tablet drug)
What this could lead to: If successful, this study could help doctors understand how to safely dose KBP-5074 in patients with liver problems.
What could go wrong: This is a very early, small study with only 12 people, so results may not apply to everyone. It only looks at safety and drug levels, not whether the drug works for any disease.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HEALTHY are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

HEALTHY MODERATE HEPATIC IMPAIRMENT

Contacts and locations

Locations

Clinical Trials of Texas (CTT)

San Antonio, Texas, 78229, United States
Orlando Clinical Research Center (OCRC)

Orlando, Florida, 32809, United States
Texas Liver Institute (TLI)

San Antonio, Texas, 78215, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.